CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 13 enrolled
Drug / intervention
Pemetrexed, Carboplatin, Pembrolizumab +1 moredrug
Likely dose
Pemetrexed, Carboplatin, Pembrolizumab 500mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04967417
NCT04967417Phase 2Completed
CompareCT.gov

Pembrolizumab With Standard Cytotoxic Chemotherapy in Treatment Naive Non-small Cell Lung Cancer Patients With Asymptomatic Brain Metastases

Samsung Medical Center·interventional·Posted Jul 19, 2021·Updated May 9, 2025

In Brief

A Phase 2 clinical trial evaluating Pemetrexed, Carboplatin, Pembrolizumab and Paclitaxel, Carboplatin, Pembrolizumab for Non-small Cell Lung Cancer. Completed, enrolled 13 participants across 1 site.

Detailed Summary

This is a Phase II single center, open-label, single arm study in patients with advanced non-small cell lung cancer (stage IV) with brain metastases. This study will be treated with combination of Pembrolizumab 200mg plus platinum doublet based on histology subtypes.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-small Cell Lung Cancer
CountriesSouth Korea
Collaborators--

Timeline

Phase 2CompletedFinished
20222023202420252026
First PostedJul 19, 2021
Enrollment StartMay 26, 2022
Primary CompletionJun 30, 2024
Study CompletionDec 2, 2024
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 5.0 years ago

Interventions

Pemetrexed, Carboplatin, Pembrolizumabdrug

* Pemetrexed 500mg/m2 * Carboplatin AUC 5.0 * Pembrolizumab 200mg

Paclitaxel, Carboplatin, Pembrolizumabdrug

* Paclitaxel 200mg/m2 * Caboplatin AUC 6.0 * Pembrolizumab 200mg